MK 0679

Known as: MK-0679, MK-679 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1991-2012
02419912012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
BACKGROUND Cysteinyl leukotrienes (CysLTs) play a major role in the pathogenic changes of airway inflammation in asthma treatment… (More)
Is this relevant?
2000
2000
Cysteinyl leukotrienes (LTs), including LTC(4), LTD(4), and LTE(4), are well known to induce bronchoconstriction and increase… (More)
Is this relevant?
1996
1996
BACKGROUND The two main features of asthma are bronchial hyperresponsiveness and inflammation. The inflammatory response in… (More)
Is this relevant?
1995
1995
Verlukast (MK-0679) is a potent leukotriene D4 antagonist that was under development for the treatment of bronchial asthma. A… (More)
Is this relevant?
1993
1993
Drugs which block the action or formation of the cysteinyl leukotrienes (LTC4, LTD4 and LTE4) inhibit asthmatic responses evoked… (More)
  • table 1
  • figure I
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1993
1993
BACKGROUND The cysteinyl leukotrienes (LTC4, LTD4, and LTE4) have been shown to mediate airway obstruction evoked by several… (More)
Is this relevant?
1993
1993
Descriptive studies suggest an association between the release of the cysteinyl leukotrienes and clinical asthma. To help clarify… (More)
Is this relevant?
1992
1992
The safety, tolerability and bronchodilator properties of inhaled verlukast (MK-0679), a new potent and selective LTD4-receptor… (More)
Is this relevant?
1992
1992
Verlukast, (S)3-((((3-(2-(7-chloroquinolin-2-yl)-(E)-ethenyl)phenyl)- 3-dimethylamino-3-oxopropylthio)methyl)thio)propionic acid… (More)
Is this relevant?
1991
1991
Verlukast (MK-679) (3-[(3-(2-(7-chloro-2-quinolinyl)-(E)-ethenyl)phenyl)[3-(dimethylamino)- 3- oxopropyl)thio)methyl)-thio… (More)
Is this relevant?